| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Brawn Biotech Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹27.47 |
| 52 Week High | ₹27.47 |
| 52 Week Low | ₹14.36 |
| Beta | 0.95 |
| 1 Month Change | 5.37% |
| 3 Month Change | 14.46% |
| 1 Year Change | 82.28% |
| 3 Year Change | -16.76% |
| 5 Year Change | -21.40% |
| Change since IPO | 254.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| 530207 | IN Healthcare | IN Market | |
|---|---|---|---|
| 7D | 0% | -1.4% | -1.9% |
| 1Y | 82.3% | 39.8% | 41.0% |
Return vs Industry: 530207 exceeded the Indian Healthcare industry which returned 39.8% over the past year.
Return vs Market: 530207 exceeded the Indian Market which returned 41% over the past year.
Price Volatility
| 530207 volatility | |
|---|---|
| 530207 Average Weekly Movement | 9.3% |
| Healthcare Industry Average Movement | 5.9% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in IN Market | 9.4% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: 530207's share price has been volatile over the past 3 months.
Volatility Over Time: 530207's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1985 | 17 | Amit Kumar | www.brawnbiotech.com |
Brawn Biotech Limited trades in pharmaceutical products in India. It offers various pharmaceutical formulations, including antibacterial, cardiovascular, antidiabetic, analgesic, gastrointestinal, antifungal, skin care, antipsychotic, antiasthmatic, antacid, antimalarial, and nutritional products. The company was formerly known as Brawn Pharmaceuticals Limited and changed its name to Brawn Biotech Limited in November 2010.
Brawn Biotech Limited Fundamentals Summary
| 530207 fundamental statistics | |
|---|---|
| Market cap | ₹82.42m |
| Earnings (TTM) | -₹12.40m |
| Revenue (TTM) | ₹212.70m |
0.4x
P/S Ratio-6.6x
P/E RatioIs 530207 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 530207 income statement (TTM) | |
|---|---|
| Revenue | ₹212.70m |
| Cost of Revenue | ₹185.10m |
| Gross Profit | ₹27.60m |
| Other Expenses | ₹40.00m |
| Earnings | -₹12.40m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.13 |
| Gross Margin | 12.98% |
| Net Profit Margin | -5.83% |
| Debt/Equity Ratio | 0% |
How did 530207 perform over the long term?
See historical performance and comparison